Efficacy of rilmenidine, A selective I1 imidazoline receptor binding agent in diabetic hypertensive patients

被引：7
|
作者：
Dupuy, O [1 ]
Bauduceau, B [1 ]
Mayaudon, H [1 ]
机构：
[1] Hop Begin, St Mande, France
来源：
AMERICAN JOURNAL OF HYPERTENSION | 2000年 / 13卷 / 06期
关键词：
rilmenidine; type; 2; diabetes; hypertension; I-1 imidazoline receptor binding;
D O I：
10.1016/S0895-7061(00)00227-2
中图分类号：
R6 [外科学];
学科分类号：
1002 ; 100210 ;
摘要：
Hypertension is a frequent complication in diabetes, and microalbuminuria has become an essential index of cardiovascular prognosis in type 2 diabetics. The pilot study reported here shows that rilmenidine, in addition to its antihypertensive action and good clinical tolerability, has the further advantage of reducing microalbuminuria, similar to captopril. Am J Hypertens 2000;13:123S-126S (C) 2000 American Journal of Hypertension, Ltd.
引用
收藏
页码：123S / 126S
页数：4
相关论文
共 50 条
  • [41] Direct evidence for imidazoline (I1) receptor modulation of ethanol action on norepinephrine-containing neurons in the rostral ventrolateral medulla in conscious spontaneously hypertensive rats
    Li, Guichu
    Abdel-Rahman, Abdel A.
    ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH, 2007, 31 (04) : 684 - 693
  • [42] CENTRAL BLOOD-PRESSURE REGULATION - CURRENT FINDINGS ON EFFICACY OF MOXONIDINE, A SELECTIVE I(1)-IMIDAZOLINE RECEPTOR AGONIST
    SOLLNER, B
    PERFUSION, 1994, 7 (12): : 464 - 465
  • [43] Efficacy and tolerability of long-term rilmenidine treatment in hypertensive diabetic patients: A retrospective analysis of a general practice study
    Meredith P.A.
    Reid J.L.
    American Journal of Cardiovascular Drugs, 2004, 4 (3) : 195 - 200
  • [44] Opposite to α2-adrenergic agonists, an imidazoline I1 selective compound does not influence reflex bradycardia in rabbits
    Sy, Guata Yoro
    Bousquet, Pascal
    Feldman, Josiane
    AUTONOMIC NEUROSCIENCE-BASIC & CLINICAL, 2006, 128 (1-2): : 19 - 24
  • [45] The Use of the Selective Imidazoline I1 Receptor Agonist Carbophenyline as a Strategy for Neuropathic Pain Relief: Preclinical Evaluation in a Mouse Model of Oxaliplatin-Induced Neurotoxicity
    Laura Micheli
    Lorenzo Di Cesare Mannelli
    Fabio Del Bello
    Mario Giannella
    Alessandro Piergentili
    Wilma Quaglia
    Donatello Carrino
    Alessandra Pacini
    Carla Ghelardini
    Neurotherapeutics, 2020, 17 : 1005 - 1015
  • [46] Protective effect of moxonidine on ischemiaireperfusion-induced acute kidney injury through α2/imidazoline I1 receptor
    Tsutsui, Hidenobu
    Sugiura, Takahiro
    Hayashi, Kentaro
    Yukimura, Tokihito
    Ohkita, Mamoru
    Takaoka, Masanori
    Matsumura, Yasuo
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2013, 718 (1-3) : 173 - 180
  • [47] I1 Imidazoline Receptor: Novel Potential Cytoprotective Target of TVP1022, the S-Enantiomer of Rasagiline
    Barac, Yaron D.
    Bar-Am, Orit
    Liani, Esti
    Amit, Tamar
    Frolov, Luba
    Ovcharenko, Elena
    Angel, Itzchak
    Youdim, Moussa B. H.
    Binah, Ofer
    PLOS ONE, 2012, 7 (11):
  • [48] Effects of the I1 imidazoline/α2-adrenergic receptor agonist moxonidine in comparison with clonidine in the formalin test in rats
    Shannon, HE
    Lutz, EA
    PAIN, 2000, 85 (1-2) : 161 - 167
  • [49] Activation of imidazoline I1 receptor by moxonidine regulates the progression of liver fibrosis in the Nrf2-dependent pathway
    Zhang, Wenfeng
    Li, Xuanfei
    Liu, Yanmin
    Chen, Hao
    Gong, Jianping
    BIOMEDICINE & PHARMACOTHERAPY, 2017, 90 : 821 - 834
  • [50] Disturbance of I1-imidazoline receptor signal transduction in cardiomyocytes of Spontaneously Hypertensive Rats
    Maltsev, Alexander V.
    Evdokimovskii, Edward V.
    Kokoz, Yury M.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2019, 671 : 62 - 68
12345